494 related articles for article (PubMed ID: 30680672)
1. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Beinhardt S; Al-Zoairy R; Kozbial K; Stättermayer AF; Maieron A; Stauber R; Strasser M; Zoller H; Graziadei I; Rasoul-Rockenschaub S; Trauner M; Ferenci P; Hofer H
Liver Int; 2018 Jul; 38(7):1188-1197. PubMed ID: 29197145
[TBL] [Abstract][Full Text] [Related]
3. Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals.
Tanaka S; Shinkawa H; Tamori A; Takemura S; Takahashi S; Amano R; Kimura K; Ohira G; Kawada N; Kubo S
J Surg Oncol; 2020 Dec; 122(8):1543-1552. PubMed ID: 32856301
[TBL] [Abstract][Full Text] [Related]
4. Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
Turgeon MK; Shah SA; Delman AM; Tran BV; Agopian VG; Wedd JP; Magliocca JF; Kim A; Cameron A; Olyaei A; Orloff SL; Anderson MP; Kubal CA; Cannon RM; Locke JE; Simpson MA; Akoad ME; Wongjirad CP; Emamaullee J; Moro A; Aucejo F; Feizpour CA; Vagefi PA; Nguyen MH; Esquivel CO; Dhanireddy K; Subramanian V; Chavarriaga A; Kazimi MM; Anderson MS; Sonnenday CJ; Kim SC; Foley DP; Abdouljoud M; Salgia RJ; Moris D; Sudan DL; Ganesh SR; Humar A; Doyle M; Chapman WC; Maithel SK
Ann Surg; 2021 Oct; 274(4):613-620. PubMed ID: 34506316
[TBL] [Abstract][Full Text] [Related]
5. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment.
Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH
Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431
[TBL] [Abstract][Full Text] [Related]
6. Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
Ji F; Yeo YH; Wei MT; Ogawa E; Enomoto M; Lee DH; Iio E; Lubel J; Wang W; Wei B; Ide T; Preda CM; Conti F; Minami T; Bielen R; Sezaki H; Barone M; Kolly P; Chu PS; Virlogeux V; Eurich D; Henry L; Bass MB; Kanai T; Dang S; Li Z; Dufour JF; Zoulim F; Andreone P; Cheung RC; Tanaka Y; Furusyo N; Toyoda H; Tamori A; Nguyen MH
J Hepatol; 2019 Sep; 71(3):473-485. PubMed ID: 31096005
[TBL] [Abstract][Full Text] [Related]
7. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.
Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND
Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729
[TBL] [Abstract][Full Text] [Related]
8. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.
Ooka Y; Miho K; Shuntaro O; Nakamura M; Ogasawara S; Suzuki E; Yasui S; Chiba T; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N; Mochizuki H; Omata M
Hepatol Int; 2018 Nov; 12(6):523-530. PubMed ID: 30242733
[TBL] [Abstract][Full Text] [Related]
9. Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature.
Obed A; Bashir A; Jarrad A
Am J Case Rep; 2016 Sep; 17():672-5. PubMed ID: 27647003
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
Waziry R; Hajarizadeh B; Grebely J; Amin J; Law M; Danta M; George J; Dore GJ
J Hepatol; 2017 Dec; 67(6):1204-1212. PubMed ID: 28802876
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness of Direct-Acting Antiviral Treatment in Hepatitis C-Infected Liver Transplant Candidates With Compensated Cirrhosis and Hepatocellular Carcinoma.
Salazar J; Saxena V; Kahn JG; Roberts JP; Mehta N; Volk M; Lai JC
Transplantation; 2017 May; 101(5):1001-1008. PubMed ID: 27926593
[TBL] [Abstract][Full Text] [Related]
12. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy.
Nagaoki Y; Imamura M; Nishida Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Fujino H; Nakahara T; Kawaoka T; Tsuge M; Hiramatsu A; Kawakami Y; Miki D; Hiyama Y; Ochi H; Chayama K; Aikata H
J Med Virol; 2019 Apr; 91(4):650-658. PubMed ID: 30381831
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular Carcinoma Is a Negative Predictor of Sustained Viral Response in Liver Transplant Recipients With Hepatitis C Treated With Direct-Acting Antivirals.
Cieciura T; Urbanowicz A; Foroncewicz B; Hryniewiecka E; Pączek L; Ciszek M
Transplant Proc; 2020 Oct; 52(8):2450-2453. PubMed ID: 32241637
[TBL] [Abstract][Full Text] [Related]
14. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma.
Persico M; Aglitti A; Aghemo A; Rendina M; Lleo A; Ciancio A; Di Marco V; Lampertico P; Brunetto MR; Zuin M; Andreone P; Villa E; Troshina G; Calvaruso V; Degasperi E; Coco B; Giorgini A; Conti F; Di Leo A; Marzi L; Boccaccio V; Bollani S; Maisonneuve P; Bruno S
Aliment Pharmacol Ther; 2018 Jun; 47(12):1705-1712. PubMed ID: 29722439
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
16. Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation.
Ryu T; Takami Y; Wada Y; Tateishi M; Matsushima H; Yoshitomi M; Mikagi K; Saitsu H
Hepatol Int; 2018 Mar; 12(2):149-157. PubMed ID: 29488056
[TBL] [Abstract][Full Text] [Related]
17. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
Beig J; Orr D; Harrison B; Gane E
Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
[TBL] [Abstract][Full Text] [Related]
19. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review.
Singal AG; Lim JK; Kanwal F
Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469
[TBL] [Abstract][Full Text] [Related]
20. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection.
Kobayashi M; Suzuki F; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Mar; 89(3):476-483. PubMed ID: 27531586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
